All Press Releases

Brand Institute's SVP of Creative Nomenclature Analyzes FDA's Novel Drug Brand Name Approvals for 2022

In 2022, 37 brand names were approved for novel drugs by the FDA. Alexa Lash, Brand Institute's Senior Vice President of Creative Nomenclature, offers some insights.

Jan 20, 2023

Drug Safety Institute's Global President Sees Promise in New mRNA Vaccine Applications in a Post-Pandemic World

Brand Institute, the global leader in pharmaceutical and healthcare-related name development, considers mRNA vaccines for the treatment of cancer to be an exciting area of research that, though still in its infancy, will continue to grow. In fact, there is a growing body of evidence to suggest that mRNA vaccines could be a powerful tool in the fight against cancer.

Dec 12, 2022

Brand Institute's Courtney Kilroy Outlines the Benefits of Early Clinical Trial Branding

Brand Institute, the world's #1 naming agency and the global leader in pharmaceutical and healthcare-related name development, is pleased to share insights on emerging clinical trial naming trends.

Dec 07, 2022

Brand Institute Partners on Nonproprietary Name for Novel Protein Degrader Under Development by Arvinas, Inc.

Brand Institute, the world's #1 naming agency and the global leader in pharmaceutical and healthcare-related name development, is pleased to announce its successful partnership with Arvinas, Inc. on the development of the nonproprietary name bavdegalutamide.

Dec 05, 2022

Bavarian Nordic's JYNNEOS Vaccine Selected by TIME Magazine as One of the Best Inventions of 2022

Brand Institute, the global leader in pharmaceutical and healthcare-related brand name and identity development, is pleased to share that Denmark-based Bavarian Nordic's smallpox and monkeypox vaccine, named JYNNEOS®, was selected by TIME Magazine as one of the best inventions of 2022.

Nov 28, 2022

Drug Safety Institute & NSU College of Pharmacy Present Alexios Skarlatos, Chair of the EMA's Name Review Group (NRG), with the 15th Annual National Patient Safety Award

Brand Institute is delighted to announce the recipient of the 15th annual Stephanie F. Aleong, J.D., National Patient Safety Award.

Nov 21, 2022

Brand Institute Partners on Brand Name Development for FDA-Approved Treatment for Pulmonary Arterial Hypertension to Improve Exercise Ability

Brand Institute is proud to announce its work with CMP Pharma in developing the brand name TADLIQ®, for tadalafil oral suspension, which was approved by the FDA on June 17, 2022.

Nov 09, 2022

Bavarian Nordic's JYNNEOS Vaccine Selected by TIME Magazine as One of the Best Inventions of 2022

Brand Institute, the global leader in pharmaceutical and healthcare-related brand name and identity development, is pleased to share that Denmark-based Bavarian Nordic's smallpox and monkeypox vaccine, named JYNNEOS®, was selected by TIME Magazine as one of the best inventions of 2022.

Nov 28, 2022

Brand Institute Partners on Brand Name Development for FDA-Approved Treatment for Congestion Due to Fluid Overload in Heart Failure Patients

Brand Institute is proud to announce its work with scPharmaceuticals in developing the brand name FUROSCIX®, which was approved by the FDA on October 7, 2022.

Nov 07, 2022

Brand Institute Partners on Brand Name Development for FDA-Approved Biologic Medication for the Treatment of Cancer

Brand Institute is proud to announce its work with Celltrion Healthcare in developing the brand name VEGZELMA®, which was approved by the FDA on September 27, 2022.

Oct 19, 2022

Drug Safety Institute's President of Canadian Regulatory Affairs on the Impact of the Quebec's Bill 96

Drug Safety Institute's President of Canadian Regulatory Affairs, Scott Sawler, is pleased to offer insight on how the Québec legislation, An Act respecting French, the official and common language of Québec may impact the use of trademarked drug brand names on product packaging.

Oct 18, 2022

Brand Institute Partners on Brand Name Development for FDA-Approved Treatment for Prevention of Postoperative Nausea and Vomiting (PONV) in Adults

Brand Institute is proud to announce its work with Heron Therapeutics in developing the brand name APONVIE™, which was approved by the FDA September 16, 2022.

Sep 28, 2022

Brand Institute Partners on Corporate Rebrand for Clinical Stage Biotechnology Company

Brand Institute is proud to announce its work with Celsion Corporation in developing its new corporate name, Imunon, which was announced on September 19, 2022. The change of name reflects the evolution of the company's business – with a focus on and commitment to developing innovative immunotherapies and next-generation vaccines to treat cancer and infectious diseases.

Sep 26, 2022

Brand Institute Celebrates 20-Year Anniversary of Expansion into Europe

Brand Institute, the world's #1 naming agency, is proud to celebrate the 20-year anniversary of the company's expansion into Europe. Brand Institute opened its first office in New York City in 1993. Ten years later, after opening five additional U.S. Offices and moving its corporate headquarters to Miami, Florida, Brand Institute opened an office in Geneva, Switzerland. The company's office in Switzerland has since moved to Basel, and two additional offices in London, England and Frankfurt, Germany have since opened.

Sep 21, 2022

Brand Institute Partners on Brand Name and Nonproprietary Name Development for FDA Approved Injection for Frown Lines

Brand Institute is proud to announce its work with Revance Therapeutics in developing the brand name DAXXIFY™, which was approved by the FDA on September 7, 2022. Brand Institute was also involved in the development of the corresponding nonproprietary name "daxibotulinumtoxinA-lanm."

Sep 12, 2022

Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Active Benign Gastric Ulcer and Reduction of Risk of Upper Gastrointestinal Bleeding in Critically Ill Patients

Brand Institute is proud to announce its work with Azurity Pharmaceuticals (formerly CutisPharma) in developing the brand name KONVOMEP™, which was approved by the FDA on August 30, 2022.

Sep 07, 2022

Brand Institute Partners on Brand Name Development for FDA Approved Hormonal Contraceptive Ring for the Prevention of Pregnancy

Brand Institute is proud to announce its work with Mayne Pharma in developing the brand name HALOETTE®.

Aug 29, 2022

Brand Institute to Moderate Round Table on Pharmaceutical Brand Naming Hosted by Harvard Business School Healthcare Alumni Association

Brand Institute is pleased to announce that it will be moderating a Virtual Round Table (VRT) hosted by the Harvard Business School Healthcare Alumni Association (HBSHAA) titled: The Pursuit of a Global Pharmaceutical Brand Name.

Aug 23, 2022

Brand Institute's Vice President of Market Research and Commercial Strategy on the Importance of Market Research Panels in Brand Development

Brand Institute's Vice President of Market Research and Commercial Strategy, Joe Bazerghi, who spearheaded the expansion of Brand Institute's market research panel of health care providers and patients across 180 countries, offers sage advice on the importance of market research panels in naming and brand development.

Aug 15, 2022

Brand Institute's Head of Trademarks on the Impact of the US Trademark Modernization Act of 2020 (TMA)

Brand Institute's Head of Trademarks, Rogelio Reyes, Esq., is pleased to offer a summary regarding the Trademark Modernization Act of 2020 (TMA), which took effect on December 18, 2021.

Aug 10, 2022

Brand Institute Partners on Brand Name Development for FDA Approved Treatment to Help Retinal Disease Patients Maintain or Gain Vision

Brand Institute is proud to announce its work with Coherus BioSciences in developing the brand name CIMERLI™ (ranibizumab-eqrn), under which the interchangeable biosimilar approved by the Food and Drug Administration (FDA) on August 2, 2022, will be marketed.

Aug 08, 2022

Brand Institute President of Nonproprietary Naming Division Advises Clients on Guidance Set Forth by INN Regarding COVID-19 Variant Vaccines

Brand Institute's President of its Nonproprietary Naming Division, Sophia Fuerst, M.S., M.B.A., is pleased to offer summary insights regarding recently implemented procedures for international nonproprietary names (INNs), specifically INNs for Variant COVID-19 Vaccine Active Substances.

Aug 03, 2022

Brand Institute's Jerry Phillips on the Impact of the FDA's Proposed Rule to Modify the NDC and Barcode Regulations

Brand Institute (BI) is pleased to share President of Regulatory Strategy Jerry Phillips' summary on the recent FDA proposal to modify its regulations to establish a uniform, 12-digit format for the National Drug Code (NDC) (21 CFR 207.33) that can accommodate longer NDCs once the FDA begins issuing 6-digit labeler codes.

Jul 27, 2022

Brand Institute Welcomes Former Amgen Associate General Counsel and Executive Director Timothy J. Gaul as Vice President of Intellectual Property Strategy

Brand Institute is pleased to announce the appointment of Timothy J. Gaul to the role of Vice President, Intellectual Property Strategy.

Jul 25, 2022

Brand Institute's President of Canadian Regulatory Affairs Updates Brand Name Assessment Methodology Based on Health Canada Trends

Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is pleased to announce new processes in its workflow.

Jul 21, 2022

Brand Institute Partners on Brand Name Development for Treatment of Relapsed or Refractor Peripheral T-Cell Lymphoma Now Approved by Ministry of Health, Labour and Welfare (Japan)

Brand Institute is proud to announce its work with Solasia Pharma K.K. ("Solasia") in developing the brand name DARVIAS®.

Jul 05, 2022

Brand Institute SVP of Nonproprietary Naming Division Shares Naming Guidance on Evolving Nomenclature Schemes Set Forth by Regulatory Agencies (USAN and INN)

Brand Institute's Senior Vice President of Regulatory Affairs for the company's Nonproprietary Naming Division, Sandra Van Laan, B.S., is pleased to share new guidance on monoclonal antibody naming, published by INN in November 2021.

Jun 27, 2022

Brand Institute Partners on Brand Name Development for European Commission Authorized Vaccine for the Prevention of Hepatitis B

Brand Institute is proud to announce its work with VBI Vaccines in developing the brand name PreHevbri™.

Jun 27, 2022

Brand Institute Executive, a Former FDA Team Leader, Celebrates 15 Years with Company's Subsidiary, Drug Safety Institute

Brand Institute, the global leader in pharmaceutical and healthcare-related name development, recently celebrated the 15-year anniversary of former FDA Team Leader, Dr. Nora Roselle, with Brand Institute/Drug Safety Institute.

Jun 23, 2022

Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Febrile Neutropenia in Cancer Patients

Brand Institute is proud to announce having worked with Adello Biologics (acquired by Kashiv Biosciences in 2019) in developing the brand name FYLNETRA® (pegfilgrastim-pbbk), for an injection used to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Jun 21, 2022

Former FDA DMEPA Director and Head of Brand Institute's Regulatory Division Updates the Company's Services Based on Recent FDA Safety Guidance

Brand Institute, the global leader in pharmaceutical and healthcare related name development, is pleased to announce incorporation of the principles and recommendations from the finalized US Food and Drug Administration FDA guidance, Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors, into the company's label/labeling design and review services

Jun 15, 2022

FDA Approves RADICAVA ORS® (edaravone) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS) by Mitsubishi Tanabe

Brand Institute is proud to announce working with Mitsubishi Tanabe in developing the brand name Radicava ORS®, approved by the Food and Drug Administration (FDA) on May 12, 2022. FDA approved Radicava ORS (edaravone) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS).

May 26, 2022

Fujifilm's FIPAS™ Service Offers High-Tech Solution for Infrastructure Maintenance

Brand Institute is proud to announce having worked with Fujifilm Corporation in developing the FIPAS™ brand name. FIPAS™ is a photo analysis service that utilizes cloud-based software to automatically identify deteriorations in concrete from photos and estimate their size.

May 23, 2022

Hyundai Updates Award Winning Venue® SUV for 2022

Brand Institute is proud to announce having worked with Hyundai Motor Company in developing the brand name Venue®. Hyundai's Venue® recently received a 5-Year Cost to Own recognition award from Kelley Blue Book for a third consecutive year.

May 19, 2022

FDA Approves Orphalan's CUVRIOR™ (trientine tetrahydrochloride), the first treatment for Wilson's disease in over five decades

Brand Institute is proud to announce working with rare disease specialist, Orphalan, in developing the brand name CUVRIOR™, approved by the United States Food and Drug Administration on April 28, 2022.

May 04, 2022

FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience

Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed.

Apr 18, 2022

FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., developed by Lipocine Inc.

Brand Institute is proud to announce working with Lipocine Inc. in developing the brand name TLANDO®, approved by the Food and Drug Administration (FDA) on March 28, 2022.

Apr 25, 2022

Fernando González Díaz to Design Brand Institute's New Corporate Office in Puerto Rico

As Brand Institute expands its operations in San Juan, Puerto Rico, it is proud to announce that it has enlisted Fernando González Díaz, Founder & Principal of Urban Venture Group (UVG), to design the company's new corporate office located at the Ritz-Carlton Reserve Dorado Beach Resort

Apr 19, 2022

FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience

Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed.

Apr 18, 2022

Oasmia announces completion of name change to Vivesto

Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, announces that as of today, 28 March, its new name, Vivesto AB, has been registered with the Swedish Companies Registration Office.

Mar 28, 2022

Maxim Biomedical's ClearDetect™ COVID-19 Antigen Home Test Receives Emergency Use Authorization (EUA) from the U.S. FDA

Brand Institute is proud to announce its successful partnership with Maxim Biomedical (MaximBio) in naming their MaximBio ClearDetect™ COVID-19 Antigen Home Test.

Feb 22, 2022

Carlos Beltrán Baseball Academy (CBBA) Partners with Global Naming Agency Brand Institute

Brand Institute is proud to announce its support and enthusiastic patronage of the Carlos Beltrán Baseball Academy (CBBA), a prestigious high school in Florida, Puerto Rico, that specializes in teaching baseball, academics, and the personal development of their students.

Feb 3, 2022

FDA Approves SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine

Brand Institute is proud to announce its successful partnership with Moderna in naming their FDA-approved COVID-19 vaccine: SPIKEVAX®, the second COVID-19 vaccine to be fully approved by the regulatory agency.

Feb 1, 2022

Brand Institute Appoints William (Bill) Johnson to Co-Chief Executive Officer & President

Brand Institute is pleased to announce the appointment of William (Bill) Johnson to the role of Co-Chief Executive Officer and President. Mr. Johnson is a naming-industry veteran and 24-year employee of Brand Institute, Inc.

Jan 24, 2022

Brand Institute Partners on Brand Name Development for FDA Approved Hormonal Contraceptive Ring for the Prevention of Pregnancy

Brand Institute is proud to announce its work with Mayne Pharma in developing the brand name HALOETTE®.

Aug 29, 2022

Brand Institute to Moderate Round Table on Pharmaceutical Brand Naming Hosted by Harvard Business School Healthcare Alumni Association

Brand Institute is pleased to announce that it will be moderating a Virtual Round Table (VRT) hosted by the Harvard Business School Healthcare Alumni Association (HBSHAA) titled: The Pursuit of a Global Pharmaceutical Brand Name.

Aug 23, 2022

FDA Approves TEZSPIRE™ (tezepelumab-ekko), AstraZeneca and Amgen's First-in-Class Treatment for Severe Asthma

Brand Institute is proud to announce its successful partnership with AstraZeneca and Amgen in naming TEZSPIRE™, the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients.

Dec 22, 2021

EMA Approves NUVAXOVID®, Novavax's COVID-19 Vaccine

Brand Institute is proud to announce its successful partnership with Novavax in naming their EMA-approved COVID-19 vaccine: NUVAXOVID®.

Dec 21, 2021

Japan's MHLW Approves Booster Shot for SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine

Brand Institute is proud to announce its successful partnership with Moderna in naming their mRNA COVID-19 vaccine: SPIKEVAX®.

Dec 19, 2021

FDA Approves Allergan's VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First Eye Drop Approved to Treat Age-Related Presbyopia in Adults

Brand Institute is proud to announce its successful partnership with Allergan, Inc., an AbbVie company, in naming VUITY™, the first and only treatment approved by the U.S. Food & Drug Administration (FDA) to treat age-related blurry near vision (Presbyopia).

Dec 13, 2021

FDA Issues Emergency Use Authorization For Astrazeneca's Evusheld™ (Tixagevimab Co-packaged With Cilgavimab), The First Antibody Therapy Authorized In The U.S. For Pre-exposure Prophylaxis Of COVID-19

Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD™ and assisting with the development of the nonproprietary names tixagevimab and cilgavimab, together denoting the first long-acting antibody combination authorized for emergency use by the U.S. Food and Drug Administration (FDA) for pre-exposure prevention of COVID-19.

Dec 10, 2021

MHRA Approves XEVUDY® (sotrovimab), GlaxoSmithKline and Vir Biotechnology's Monoclonal Antibody Treatment for Patients with COVID‑19

Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY®, a monoclonal antibody therapeutic approved for symptomatic adults and adolescents (12 years of age and older) with acute COVID–19 infection.

Dec 07, 2021

FDA Approves Takeda's Livtencity™ (maribavir), First Treatment Approved for Post-Transplant Cytomegalovirus (CMV) Infection Resistant to Other Drugs

Brand Institute is proud to announce its successful partnership with Takeda Pharmaceuticals Company Limited in naming the first treatment approved by the US Food & Drug Administration (FDA) for adults and pediatric patients with post-transplant cytomegalovirus (CMV) infection that does not respond to available antiviral treatment for CMV.

Nov 24, 2021

ImaginAb announces partnership with Brand Institute to develop a global brand name for CD8 ImmunoPET Technology

ImaginAb Inc, a market-leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and radiopharmaceutical therapy (RPT), today announced it will be partnering with Miami-based branding agency, Brand Institute, on the development of a global brand name for ImaginAb’s CD8 ImmunoPET technology.

Oct 29, 2021

Health Canada Approves COVID-19 Vaccine Brand Names Comirnaty®, Spikevax® and Vaxzevria® for Pfizer/BioNTech, Moderna and AstraZeneca, Respectively

Brand Institute is proud to announce its role in naming all three COVID-19 vaccine brand names recently approved by Health Canada: Comirnaty® (Pfizer/BioNTech), Spikevax® (Moderna), and Vaxzevria® (AstraZeneca).

Sep 20, 2021

FDA Approves COMIRNATY®, The First COVID-19 Vaccine Approved By The Agency And The First COVID-19 Vaccine Brand Name Approved In The U.S.

Brand Institute is proud to announce its role in naming Pfizer and BioNTech's FDA-approved COVID-19 vaccine: COMIRNATY® (koe mir' na tee).

Aug 25, 2021

Vaxzevria® Brand Naming Strategy and Logo Revealed

Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is proud to share the official logo and creative naming strategy for AstraZeneca's COVID-19 vaccine: Vaxzevria® (vax zev' ree ah).

Jul 22, 2021

Introducing COMIRNATY®, the EU Brand Name forPfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute

Brand Institute, the global leader in pharmaceutical and healthcare related name development, is proud to announce its role in naming Pfizer and BioNTech's COVID-19 vaccine: COMIRNATY® (koe mir' na tee).

Dec 28, 2020